Zatosetron

From Self-sufficiency
Revision as of 19:16, 29 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Zatosetron
220px
Systematic (IUPAC) name
5-​chloro-​2,2-​dimethyl-​N-​(8-​methyl-​8-​azabicyclo​[3.2.1]oct-​3-​yl)-​2,3-​dihydro-​1-​benzofuran-​7-​carboxamide
Identifiers
CAS Number 123482-22-4
ATC code none
PubChem CID 60763
Chemical data
Formula C19H25ClN2O2
Molar mass 348.867 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Zatosetron (LY-277,359) is a drug which acts as an antagonist at the 5HT3 receptor[1] It is orally active and has a long duration of action, producing antinauseant effects but without stimulating the rate of gastrointestinal transport.[2][3] It is also an effective anxiolytic in both animal studies and human trials,[4] although with some side effects at higher doses.[5][6]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />



  1. Cohen ML, Bloomquist W, Gidda JS, Lacefield W. LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity. Journal of Pharmacology and Experimental Therapeutics. 1990 Jul;254(1):350-5. PMID 2366187
  2. Robertson DW, Lacefield WB, Bloomquist W, Pfeifer W, Simon RL, Cohen ML. Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. Journal of Medicinal Chemistry. 1992 Jan 24;35(2):310-9. PMID 1732548
  3. Schwartz SM, Goldberg MJ, Gidda JS, Cerimele BJ. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men. Journal of Clinical Pharmacology. 1994 Mar;34(3):250-4. PMID 7517409
  4. Smith WT, Londborg PD, Blomgren SL, Tollefson GD, Sayler ME. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. Journal of Clinical Psychopharmacology. 1999 Apr;19(2):125-31. PMID 10211913
  5. Williams PD, Calligaro DO, Colbert WE, Helton DR, Shetler T, Turk JA, Jordan WH. General pharmacology of a new potent 5-hydroxytryptamine antagonist. Arzneimittelforschung. 1991 Mar;41(3):189-95. PMID 1867653
  6. Bendele A, Means J, Shoufler J, Schmalz C, Hanasono G, Symanowski J, Adams E. Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys. Drug and Chemical Toxicology. 1995 Feb;18(1):61-82. PMID 7768200